HIV Reservoir Clones Remain the Key Cure Obstacle
A NEW study offers a rare window into HIV reservoir clones that can survive for life despite antiretroviral therapy (ART).
HIV latency, where the virus lies dormant in long-lived CD4+ T cells, remains the main barrier to eradication, as these infected cells can reignite viraemia if treatment stops. In this work, researchers isolated “authentic reservoir clones” (ARCs), CD4+ T cell clones that both proliferate and harbour rebound-competent virus without being rapidly destroyed.
These HIV reservoir clones showed an unusual balance: at any given time, only a small fraction of cells within a clone expressed viral proteins, limiting their visibility to the immune system. This low-level expression was tied to stable host transcriptional programmes that persisted even when the cells were exposed to strong T cell stimulation, suggesting that conventional activation is not enough to flush these reservoirs.
Persistent Immune Pressure Can Erode Reservoir Clones
Despite their resilience, ARCs were not completely invulnerable. When the researchers cocultured them with a potent CD8+ cytotoxic T lymphocyte (CTL) clone over an extended period, the proliferating HIV reservoir clones were progressively depleted. This time integrated killing indicates that sustained, high quality CTL pressure can chip away at even robust reservoirs, although the process is slow.
By contrast, CD8+ T cell responses measured ex vivo were much less effective, and erosion of ARCs in vivo appeared to occur only gradually. This gap between what highly optimised CTLs can achieve in the laboratory and what happens in patients underlines the challenge of boosting natural immunity enough to meaningfully shrink the HIV reservoir under ART.
Regulatory T-Cell Reservoirs Show Intrinsic Resistance
One ARC derived from a regulatory T cell population showed particularly strong cell-intrinsic resistance to CTL-mediated killing, confirming a longstanding hypothesis that these cells can act as protected viral sanctuaries. This resistance was linked to lower oxidative stress within the cells. When the team used deferoxamine, a hypoxic stressinducing, clinically approved drug, this resistance was reversed, making the reservoir cells more susceptible to CTL attack.
These findings suggest that targeting intrinsic resistance pathways, such as cellular stress responses, in HIV reservoir clones could enhance the impact of immune-based cure strategies. By combining sustained, high-quality CTL responses with agents that sensitise reservoir cells to killing, future therapies may be able to erode the latent reservoir more effectively and bring the goal of an HIV cure closer to reality.
Reference
Ferreira IATM et al. Dynamic antigen expression and cytotoxic T cell resistance in HIV reservoir clones. Nature. 2026; DOI:10.1038/s41586-026-10298-w.
Featured image: Corona Borealis on Adobe Stock
